Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029-Reference-Cited by-同舟云学术

Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029

Published:2015-01 Issue:1 Volume:21 Page:103.e1-103.e6
ISSN:1198-743X
Container-title:Clinical Microbiology and Infection
language:en
Short-container-title:Clinical Microbiology and Infection

Author:

Surdo M.,Alteri C.,Puertas M.C.,Saccomandi P.,Parrotta L.,Swenson L.,Chapman D.,Costa G.,Artese A.,Balestra E.,Aquaro S.,Alcaro S.,Lewis M.,Clotet B.,Harrigan R.,Valdez H.,Svicher V.,Perno C.F.,Martinez-Picado J.,Ceccherini-Silberstein F.

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference20 articles.

1. Preferential use of CXCR4 by R5X4 human immunodeficiency virus type 1 isolates for infection of primary lymphocytes;Yi;J Virol,2005

2. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression;Scarlatti;Nat Med,1997

3. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro;Svicher;Antiviral Res,2011

4. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient;Symons;J Antimicrob Chemother,2011

5. Dual-tropic HIV type 1 isolates vary dramatically in their utilization of CCR5 and CXCR4 coreceptors;Toma;AIDS,2010

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The chemokine receptor type 5 inhibitor maraviroc alleviates sepsis- associated liver injury by regulating MAPK/NF-κB signaling;2024-04-05

2. CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy;Molecules;2019-02-02

3. Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children;Medicine;2018-03

4. CXCR4-using HIV variants in a cohort of Black men who have sex with men: HIV Prevention Trials Network 061;HIV Clinical Trials;2016-06-14